Dilated Cardiomyopathy Therapeutics Market – Global Industry Analysis and Forecast (2023-2029)


Dilated Cardiomyopathy Therapeutics Market size is expected to grow at a CAGR of 6.27% during the forecast period and the market size is expected to reach nearly US$ 234.62 Mn. by 2029.

Dilated cardiomyopathy (DCM) is a cardiac disorder in simple words it is caused by an expansion of the heart. The disorder can cause effect on the livers, lungs and other important organs of the body gradually.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Global Dilated Cardiomyopathy Therapeutics MarketTo know about the Research Methodology :- Request Free Sample Report

The success of these clinical studies will boost the growth and demand for the dilated cardiomyopathy therapeutics market in forthcoming years. The rising prevalence of congestive heart failure is the major driver for the market for cardiomyopathy therapeutics, but several factors impede the growth of the dilated cardiomyopathy therapeutics market in the coming future. The availability of implantable devices, such as heart pumps, implantable cardioverter defibrillators (ICDs), and pacemakers, and the propitious development of gene therapy will hinder the growth of the dilated cardiomyopathy therapeutics market in the coming future. Additionally, the various side effects related to the usage of DCM drugs and the easier treatment with the help of other devices, which have minimal or nil side effects, will impede the growth of the dilated cardiomyopathy therapeutics market in the forthcoming future.

Based on the drug class, Angiotensin II receptor blockers held the leading revenue share of xx% in the market, trailed by beta-blockers. The reason for them acquiring the largest revenue share is their high demand in dilated cardiomyopathy treatment, mainly in the developed regions of Europe and North America. On the other hand, the aldosterone antagonists segment held the highest growth rate on account of the positive effect of the combination of aldosterone antagonists with ACE inhibitors or ARBs for reducing the progress of Duchenne muscular dystrophy (DMD).

Region-wise, in terms of revenue, North America accounted for the largest market share of xx% thanks to rising incidences of congestive heart failure and high acceptance of branded drugs. In the U.S., DCM is prevalent in approximately five to eight people out of every 100,000 people. In Canada, heart failure affects over 1% of the total population and is answerable for about 9% of all the deaths. The Asia Pacific and Rest of the World markets are the fastest-growing markets because of rising economic standards, rising disposable income and high demand for generic drugs.

The objective of the report is to present comprehensive analysis of global dilated cardiomyopathy therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global dilated cardiomyopathy therapeutics market dynamics, structure by analyzing the market segments, and project the global dilated cardiomyopathy therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global dilated cardiomyopathy therapeutics market make the report investor’s guide.

Scope of the Global Dilated Cardiomyopathy Therapeutics Market: Inquire before buying






Global Dilated Cardiomyopathy Therapeutics Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 153.2 Mn.




Forecast Period 2023 to 2029 CAGR:
6.27%
Market Size in 2029:
US $ 234.62 Mn.




 Segments Covered:
by Drug Class
• Aldosterone antagonists
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Beta-blockers




by Pipeline Drugs
• ARRY-797
• ixCELL-DCM
• MYDICAR
• OR-1
• CAP-1002






Dilated Cardiomyopathy Therapeutics Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Dilated Cardiomyopathy Therapeutics Market, Key Players are:

• Array BioPharma, Inc.
• AstraZeneca plc.
• Celladon Corporation
• GlaxoSmithKline plc.
• Janssen Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd
• Vericel Corporation
• Zensun Shanghai Sci & Tech Co Ltd
• Capricor Therapeutics, Inc
• t2cure GmbH
• MyoKardia
• Kasiak Research pvt.ltd

Frequently Asked Questions:

1. Which region has the largest share in Global Dilated Cardiomyopathy Therapeutics Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Dilated Cardiomyopathy Therapeutics Market?
Ans: The Global Dilated Cardiomyopathy Therapeutics Market is growing at a CAGR of 6.27% during forecasting period 2023-2029.

3. What is scope of the Global Dilated Cardiomyopathy Therapeutics Market report?
Ans: Global Dilated Cardiomyopathy Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Dilated Cardiomyopathy Therapeutics Market?
Ans: The important key players in the Global Dilated Cardiomyopathy Therapeutics Market are – Array BioPharma, Inc., AstraZeneca plc., Celladon Corporation, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, Vericel Corporation, Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, t2cure GmbH, MyoKardia, Kasiak Research pvt.ltd.

5. What is the study period of this Market?
Ans: The Global Dilated Cardiomyopathy Therapeutics Market is studied from 2022 to 2029. 




Global Dilated Cardiomyopathy Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Dilated Cardiomyopathy Therapeutics Market, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast
6.1. Global Dilated Cardiomyopathy Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast, by Pipeline Drugs
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
7.4. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Pipeline Drugs
7.5. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Pipeline Drugs
7.6. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Pipeline Drugs

8. Global Dilated Cardiomyopathy Therapeutics Market Analysis and Forecast, by Drug Class
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
8.4. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Drug Class
8.5. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Drug Class
8.6. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Drug Class

9. Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Region
9.1. Global Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Region
9.2. Global Dilated Cardiomyopathy Therapeutics Market Size (US$ Bn) Forecast, by Region
9.3. Global Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis, by Region

10. North America Dilated Cardiomyopathy Therapeutics Market Analysis
10.1. Key Findings
10.2. North America Dilated Cardiomyopathy Therapeutics Market Overview
10.3. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
10.4. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
10.4.1. ARRY-797
10.4.2. IxCELL-DCM
10.4.3. MYDICAR
10.4.4. OR-1
10.4.5. CAP-1002
10.5. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
10.6. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
10.6.1. Aldosterone antagonists
10.6.2. Angiotensin-converting enzyme (ACE) inhibitors
10.6.3. Angiotensin II receptor blockers (ARBs)
10.6.4. Beta-blockers
10.7. North America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country
10.8. North America Dilated Cardiomyopathy Therapeutics Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Dilated Cardiomyopathy Therapeutics Market Analysis, by Country
10.10. U.S. Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
10.10.1. ARRY-797
10.10.2. IxCELL-DCM
10.10.3. MYDICAR
10.10.4. OR-1
10.10.5. CAP-1002
10.11. U.S. Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
10.11.1. Aldosterone antagonists
10.11.2. Angiotensin-converting enzyme (ACE) inhibitors
10.11.3. Angiotensin II receptor blockers (ARBs)
10.11.4. Beta-blockers
10.12. Canada Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
10.12.1. ARRY-797
10.12.2. IxCELL-DCM
10.12.3. MYDICAR
10.12.4. OR-1
10.12.5. CAP-1002
10.13. Canada Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
10.13.1. Aldosterone antagonists
10.13.2. Angiotensin-converting enzyme (ACE) inhibitors
10.13.3. Angiotensin II receptor blockers (ARBs)
10.13.4. Beta-blockers
10.14. North America Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis
10.14.1. By Pipeline Drugs
10.14.2. By Drug Class
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Dilated Cardiomyopathy Therapeutics Market Analysis
11.1. Key Findings
11.2. Europe Dilated Cardiomyopathy Therapeutics Market Overview
11.3. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
11.4. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.4.1. ARRY-797
11.4.2. IxCELL-DCM
11.4.3. MYDICAR
11.4.4. OR-1
11.4.5. CAP-1002
11.5. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
11.6. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.6.1. Aldosterone antagonists
11.6.2. Angiotensin-converting enzyme (ACE) inhibitors
11.6.3. Angiotensin II receptor blockers (ARBs)
11.6.4. Beta-blockers
11.7. Europe Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country
11.8. Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Dilated Cardiomyopathy Therapeutics Market Analysis, by Country
11.10. Germany Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.10.1. ARRY-797
11.10.2. IxCELL-DCM
11.10.3. MYDICAR
11.10.4. OR-1
11.10.5. CAP-1002
11.11. Germany Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.11.1. Aldosterone antagonists
11.11.2. Angiotensin-converting enzyme (ACE) inhibitors
11.11.3. Angiotensin II receptor blockers (ARBs)
11.11.4. Beta-blockers
11.12. U.K. Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.12.1. ARRY-797
11.12.2. IxCELL-DCM
11.12.3. MYDICAR
11.12.4. OR-1
11.12.5. CAP-1002
11.13. U.K. Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.13.1. Aldosterone antagonists
11.13.2. Angiotensin-converting enzyme (ACE) inhibitors
11.13.3. Angiotensin II receptor blockers (ARBs)
11.13.4. Beta-blockers
11.14. France Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.14.1. ARRY-797
11.14.2. IxCELL-DCM
11.14.3. MYDICAR
11.14.4. OR-1
11.14.5. CAP-1002
11.15. France Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.15.1. Aldosterone antagonists
11.15.2. Angiotensin-converting enzyme (ACE) inhibitors
11.15.3. Angiotensin II receptor blockers (ARBs)
11.15.4. Beta-blockers
11.16. Italy Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.16.1. ARRY-797
11.16.2. IxCELL-DCM
11.16.3. MYDICAR
11.16.4. OR-1
11.16.5. CAP-1002
11.17. Italy Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.17.1. Aldosterone antagonists
11.17.2. Angiotensin-converting enzyme (ACE) inhibitors
11.17.3. Angiotensin II receptor blockers (ARBs)
11.17.4. Beta-blockers
11.18. Spain Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.18.1. ARRY-797
11.18.2. IxCELL-DCM
11.18.3. MYDICAR
11.18.4. OR-1
11.18.5. CAP-1002
11.19. Spain Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.19.1. Aldosterone antagonists
11.19.2. Angiotensin-converting enzyme (ACE) inhibitors
11.19.3. Angiotensin II receptor blockers (ARBs)
11.19.4. Beta-blockers
11.20. Rest of Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
11.20.1. ARRY-797
11.20.2. IxCELL-DCM
11.20.3. MYDICAR
11.20.4. OR-1
11.20.5. CAP-1002
11.21. Rest of Europe Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
11.21.1. Aldosterone antagonists
11.21.2. Angiotensin-converting enzyme (ACE) inhibitors
11.21.3. Angiotensin II receptor blockers (ARBs)
11.21.4. Beta-blockers
11.22. Europe Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis
11.22.1. By Pipeline Drugs
11.22.2. By Drug Class
11.23. PEST Analysis
11.24. Key Trends
11.25. Key Development

12. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Analysis
12.1. Key Findings
12.2. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Overview
12.3. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
12.4. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.4.1. ARRY-797
12.4.2. IxCELL-DCM
12.4.3. MYDICAR
12.4.4. OR-1
12.4.5. CAP-1002
12.5. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
12.6. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.6.1. Aldosterone antagonists
12.6.2. Angiotensin-converting enzyme (ACE) inhibitors
12.6.3. Angiotensin II receptor blockers (ARBs)
12.6.4. Beta-blockers
12.7. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country
12.8. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Analysis, by Country
12.10. China Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.10.1. ARRY-797
12.10.2. IxCELL-DCM
12.10.3. MYDICAR
12.10.4. OR-1
12.10.5. CAP-1002
12.11. China Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.11.1. Aldosterone antagonists
12.11.2. Angiotensin-converting enzyme (ACE) inhibitors
12.11.3. Angiotensin II receptor blockers (ARBs)
12.11.4. Beta-blockers
12.12. India Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.12.1. ARRY-797
12.12.2. IxCELL-DCM
12.12.3. MYDICAR
12.12.4. OR-1
12.12.5. CAP-1002
12.13. India Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.13.1. Aldosterone antagonists
12.13.2. Angiotensin-converting enzyme (ACE) inhibitors
12.13.3. Angiotensin II receptor blockers (ARBs)
12.13.4. Beta-blockers
12.14. Japan Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.14.1. ARRY-797
12.14.2. IxCELL-DCM
12.14.3. MYDICAR
12.14.4. OR-1
12.14.5. CAP-1002
12.15. Japan Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.15.1. Aldosterone antagonists
12.15.2. Angiotensin-converting enzyme (ACE) inhibitors
12.15.3. Angiotensin II receptor blockers (ARBs)
12.15.4. Beta-blockers
12.16. ASEAN Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.16.1. ARRY-797
12.16.2. IxCELL-DCM
12.16.3. MYDICAR
12.16.4. OR-1
12.16.5. CAP-1002
12.17. ASEAN Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.17.1. Aldosterone antagonists
12.17.2. Angiotensin-converting enzyme (ACE) inhibitors
12.17.3. Angiotensin II receptor blockers (ARBs)
12.17.4. Beta-blockers
12.18. Rest of Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
12.18.1. ARRY-797
12.18.2. IxCELL-DCM
12.18.3. MYDICAR
12.18.4. OR-1
12.18.5. CAP-1002
12.19. Rest of Asia Pacific Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
12.19.1. Aldosterone antagonists
12.19.2. Angiotensin-converting enzyme (ACE) inhibitors
12.19.3. Angiotensin II receptor blockers (ARBs)
12.19.4. Beta-blockers
12.20. Asia Pacific Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis
12.20.1. By Pipeline Drugs
12.20.2. By Drug Class
12.21. PEST Analysis
12.22. Key Trends
12.23. Key Development

13. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Overview
13.3. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
13.4. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
13.4.1. ARRY-797
13.4.2. IxCELL-DCM
13.4.3. MYDICAR
13.4.4. OR-1
13.4.5. CAP-1002
13.5. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
13.6. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
13.6.1. Aldosterone antagonists
13.6.2. Angiotensin-converting enzyme (ACE) inhibitors
13.6.3. Angiotensin II receptor blockers (ARBs)
13.6.4. Beta-blockers
13.7. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country
13.8. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Analysis, by Country
13.10. GCC Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
13.10.1. ARRY-797
13.10.2. IxCELL-DCM
13.10.3. MYDICAR
13.10.4. OR-1
13.10.5. CAP-1002
13.11. GCC Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
13.11.1. Aldosterone antagonists
13.11.2. Angiotensin-converting enzyme (ACE) inhibitors
13.11.3. Angiotensin II receptor blockers (ARBs)
13.11.4. Beta-blockers
13.12. South Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
13.12.1. ARRY-797
13.12.2. IxCELL-DCM
13.12.3. MYDICAR
13.12.4. OR-1
13.12.5. CAP-1002
13.13. South Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
13.13.1. Aldosterone antagonists
13.13.2. Angiotensin-converting enzyme (ACE) inhibitors
13.13.3. Angiotensin II receptor blockers (ARBs)
13.13.4. Beta-blockers
13.14. Rest of Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
13.14.1. ARRY-797
13.14.2. IxCELL-DCM
13.14.3. MYDICAR
13.14.4. OR-1
13.14.5. CAP-1002
13.15. Rest of Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
13.15.1. Aldosterone antagonists
13.15.2. Angiotensin-converting enzyme (ACE) inhibitors
13.15.3. Angiotensin II receptor blockers (ARBs)
13.15.4. Beta-blockers
13.16. Middle East & Africa Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis
13.16.1. By Pipeline Drugs
13.16.2. By Drug Class
13.17. PEST Analysis
13.18. Key Trends
13.19. Key Development

14. South America Dilated Cardiomyopathy Therapeutics Market Analysis
14.1. Key Findings
14.2. South America Dilated Cardiomyopathy Therapeutics Market Overview
14.3. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Pipeline Drugs
14.4. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
14.4.1. ARRY-797
14.4.2. IxCELL-DCM
14.4.3. MYDICAR
14.4.4. OR-1
14.4.5. CAP-1002
14.5. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Drug Class
14.6. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
14.6.1. Aldosterone antagonists
14.6.2. Angiotensin-converting enzyme (ACE) inhibitors
14.6.3. Angiotensin II receptor blockers (ARBs)
14.6.4. Beta-blockers
14.7. South America Dilated Cardiomyopathy Therapeutics Market Value Share Analysis, by Country
14.8. South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. South America Dilated Cardiomyopathy Therapeutics Market Analysis, by Country
14.10. Brazil Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
14.10.1. ARRY-797
14.10.2. IxCELL-DCM
14.10.3. MYDICAR
14.10.4. OR-1
14.10.5. CAP-1002
14.11. Brazil Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
14.11.1. Aldosterone antagonists
14.11.2. Angiotensin-converting enzyme (ACE) inhibitors
14.11.3. Angiotensin II receptor blockers (ARBs)
14.11.4. Beta-blockers
14.12. Mexico Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
14.12.1. ARRY-797
14.12.2. IxCELL-DCM
14.12.3. MYDICAR
14.12.4. OR-1
14.12.5. CAP-1002
14.13. Mexico Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
14.13.1. Aldosterone antagonists
14.13.2. Angiotensin-converting enzyme (ACE) inhibitors
14.13.3. Angiotensin II receptor blockers (ARBs)
14.13.4. Beta-blockers
14.14. Rest of South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Pipeline Drugs
14.14.1. ARRY-797
14.14.2. IxCELL-DCM
14.14.3. MYDICAR
14.14.4. OR-1
14.14.5. CAP-1002
14.15. Rest of South America Dilated Cardiomyopathy Therapeutics Market Forecast, by Drug Class
14.15.1. Aldosterone antagonists
14.15.2. Angiotensin-converting enzyme (ACE) inhibitors
14.15.3. Angiotensin II receptor blockers (ARBs)
14.15.4. Beta-blockers
14.16. South America Dilated Cardiomyopathy Therapeutics Market Attractiveness Analysis
14.16.1. By Pipeline Drugs
14.16.2. By Drug Class
14.17. PEST Analysis
14.18. Key Trends
14.19. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Array BioPharma, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. AstraZeneca plc.
15.3.3. Celladon Corporation
15.3.4. GlaxoSmithKline plc.
15.3.5. Janssen Pharmaceuticals, Inc.
15.3.6. Merck & Co., Inc.
15.3.7. Novartis International AG
15.3.8. Pfizer, Inc.
15.3.9. Teva Pharmaceutical Industries Ltd
15.3.10. Vericel Corporation
15.3.11. Zensun Shanghai Sci & Tech Co Ltd
15.3.12. Capricor Therapeutics, Inc
15.3.13. t2cure GmbH
15.3.14. MyoKardia
15.3.15. Kasiak Research pvt.ltd

16. Primary Key Insights
  • INQUIRE BEFORE BUYING